Tralokinumab for Dupilumab Failures

计划入组 7 人 · 首次发布于 2025 年 1 月 14 日

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

计划入组 301 人 · 首次发布于 2018 年 5 月 16 日

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)

计划入组 802 人 · 首次发布于 2017 年 4 月 27 日

Tralokinumab(Adbry, Adtralza)

Rx

LYRM-03

LDR-2402

TD GLOBAL HEALTHCARE LDRS INDX ETF UNIT

United States

Adbry (Tralokinumab) Shows Sustained Long-Term Efficacy and Safety in Atopic Dermatitis Patients: ECZTEND Trial Results

Atopic Dermatitis Market Poised for Four-Fold Growth by 2034, Driven by Novel IL-13 Inhibitor Approvals

Tralokinumab Shows Sustained Efficacy and Safety in Long-Term Atopic Dermatitis Treatment